147 related articles for article (PubMed ID: 36191992)
41. Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients After Postoperative Extended-Field Concurrent Chemoradiotherapy.
Zhang G; Miao L; Wu H; Zhang Y; Fu C
Technol Cancer Res Treat; 2021; 20():15330338211044626. PubMed ID: 34605696
[No Abstract] [Full Text] [Related]
42. Rapid involution and mobility of carcinoma of the cervix.
Lee CM; Shrieve DC; Gaffney DK
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):625-30. PubMed ID: 14751536
[TBL] [Abstract][Full Text] [Related]
43. Who can benefit from a lymph node boost in definitive chemoradiotherapy for node-positive cervical cancer: an evaluation of nodal failure in patients without nodal boost.
Kim H; Park W; Cho WK
J Radiat Res; 2020 May; 61(3):479-486. PubMed ID: 32211854
[TBL] [Abstract][Full Text] [Related]
44. HPV genotypes predict survival benefits from concurrent chemotherapy and radiation therapy in advanced squamous cell carcinoma of the cervix.
Wang CC; Lai CH; Huang YT; Chao A; Chou HH; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e499-506. PubMed ID: 22889667
[TBL] [Abstract][Full Text] [Related]
45. Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy.
Taguchi T; Nishimura G; Takahashi M; Komatsu M; Sano D; Sakuma N; Arai Y; Yamashita Y; Shiono O; Hirama M; Sakuma Y; Ishitoya J; Hata M; Ogino I; Oridate N
Cancer Chemother Pharmacol; 2013 Oct; 72(4):837-43. PubMed ID: 23959463
[TBL] [Abstract][Full Text] [Related]
46. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy.
Cho WK; Yu JI; Park HC; Lim DH; Kim TH; Chie EK
Tumori; 2021 Jun; 107(3):247-253. PubMed ID: 32646298
[TBL] [Abstract][Full Text] [Related]
47. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
[TBL] [Abstract][Full Text] [Related]
48. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
[TBL] [Abstract][Full Text] [Related]
49. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
50. Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy.
Shodo R; Yamazaki K; Ueki Y; Takahashi T; Horii A
Eur Arch Otorhinolaryngol; 2021 Jun; 278(6):2001-2009. PubMed ID: 32772234
[TBL] [Abstract][Full Text] [Related]
51. Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy.
Taguchi T; Nishimura G; Takahashi M; Komatsu M; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi H; Hata M; Koike I; Oridate N
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1147-54. PubMed ID: 24658628
[TBL] [Abstract][Full Text] [Related]
52. Concomitant Chemoradiotherapy With Image-guided Pulsed Dose Rate Brachytherapy as a Definitive Treatment Modality for Early-stage Cervical Cancer.
Refaat T; Castelain B; Small W; Elsaid A; Lotfy N; Lartigau E; Nickers P
Am J Clin Oncol; 2015 Jun; 38(3):289-93. PubMed ID: 23799285
[TBL] [Abstract][Full Text] [Related]
53. Preoperative Chemoradiotherapy in Locally Advanced Bulky Squamous Cell Carcinoma of the Uterine Cervix.
Nakao Y; Hashiguchi M; Nishiyama S; Aihara S; Iwasaka T; Yokoyama M
Int J Gynecol Cancer; 2017 Nov; 27(9):1943-1948. PubMed ID: 28786876
[TBL] [Abstract][Full Text] [Related]
54. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
[TBL] [Abstract][Full Text] [Related]
56. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.
Parker K; Gallop-Evans E; Hanna L; Adams M
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):140-6. PubMed ID: 18922646
[TBL] [Abstract][Full Text] [Related]
57. Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy.
Logsdon MD; Eifel PJ
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):763-75. PubMed ID: 10098431
[TBL] [Abstract][Full Text] [Related]
58. Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery.
Grigsby PW; Perez CA; Chao KS; Elbendary A; Herzog TJ; Rader JS; Mutch DG
Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):645-51. PubMed ID: 10524418
[TBL] [Abstract][Full Text] [Related]
59. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
